ELIZABETH DEL PRADO TAN-CHIU
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- RUSKIN, FL
- NPI
- 1538113931
- Received
- $2,490 in 45 records, 2019 to 2025
- As principal investigator
- $9,682 of research payments to others in 6 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 3 | $1,434 |
| 2024 | General payment | 1 | $13 |
| 2023 | General payment | 1 | $27 |
| 2022 | General payment | 2 | $135 |
| 2021 | General payment | 1 | $116 |
| 2020 | General payment | 21 | $454 |
| 2019 | General payment | 16 | $309 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 1 | $1,250 | 2025 |
| AstraZeneca Pharmaceuticals LP | 7 | $238 | 2019–2021 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $136 | 2019–2020 |
| Lilly USA, LLC | 1 | $121 | 2025 |
| Novocure Inc. | 1 | $78 | 2022 |
| PFIZER INC. | 1 | $63 | 2025 |
| Myriad Genetic Laboratories, Inc. | 1 | $56 | 2022 |
| Novartis Pharmaceuticals Corporation | 3 | $53 | 2019–2020 |
| GENZYME CORPORATION | 3 | $53 | 2019–2020 |
| Pharmacyclics LLC, an AbbVie Company | 2 | $46 | 2019–2023 |
| Celgene Corporation | 2 | $41 | 2019–2020 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $38 | 2019–2020 |
| E.R. Squibb & Sons, L.L.C. | 2 | $35 | 2020 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $34 | 2019–2020 |
| EMD Serono, Inc. | 1 | $25 | 2020 |
| Astellas Pharma US Inc | 1 | $24 | 2020 |
| Daiichi Sankyo Inc. | 1 | $23 | 2020 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 | 2020 |
| Genentech USA, Inc. | 1 | $20 | 2019 |
| Janssen Biotech, Inc. | 1 | $20 | 2019 |
| Merck Sharp & Dohme LLC | 1 | $18 | 2019 |
| EUSA Pharma (US) LLC | 1 | $16 | 2019 |
| TOLMAR Pharmaceuticals, Inc. | 1 | $15 | 2020 |
| Agios Pharmaceuticals, Inc. | 1 | $15 | 2020 |
| Partner Therapeutics, Inc. | 1 | $14 | 2019 |
| Amgen Inc. | 1 | $13 | 2024 |
| Secura Bio, Inc. | 2 | $13 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 1 | $1,250 |
| Food and Beverage | 44 | $1,240 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | Eli Lilly and Company | $1,250 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-10 | PFIZER INC. | $63 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-10-23 | Lilly USA, LLC | $121 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2025 | |
| 2024-02-26 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2024 | |
| 2023-12-06 | Pharmacyclics LLC, an AbbVie Company | $27 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2023 | |
| 2022-10-14 | Novocure Inc. | $78 | Food and Beverage | Cash or cash equivalent | Optune Device, Oncology | 2022 | |
| 2022-02-23 | Myriad Genetic Laboratories, Inc. | $56 | Food and Beverage | Cash or cash equivalent | myRisk Device, Germline DNA Sequencing Hereditary Cancer and Rearrangement Analysis | 2022 | |
| 2021-10-13 | AstraZeneca Pharmaceuticals LP | $116 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2021 | |
| 2020-02-28 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | MEKINIST Drug, ONCOLOGY | 2020 | |
| 2020-02-27 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2020 | |
| 2020-02-26 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | IMFINZI Drug, Oncology | 2020 | |
| 2020-02-19 | Takeda Pharmaceuticals U.S.A., Inc. | $92 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2020 | |
| 2020-02-19 | GENZYME CORPORATION | $18 | Food and Beverage | In-kind items and services | CABLIVI Biological, Hematology | 2020 | |
| 2020-02-10 | Agios Pharmaceuticals, Inc. | $15 | Food and Beverage | Cash or cash equivalent | TIBSOVO Drug, Oncology | 2020 | |
| 2020-02-06 | TOLMAR Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | ELIGARD Drug, Prostate Cancer | 2020 | |
| 2020-02-04 | E.R. Squibb & Sons, L.L.C. | $19 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2020 | |
| 2020-01-31 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | GILOTRIF Drug, ONCOLOGY | 2020 | |
| 2020-01-31 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | IMFINZI Drug, Oncology | 2020 | |
| 2020-01-27 | Daiichi Sankyo Inc. | $23 | Food and Beverage | In-kind items and services | Enhertu Drug, Oncology | 2020 | |
| 2020-01-25 | E.R. Squibb & Sons, L.L.C. | $16 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2020 | |
| 2020-01-23 | EMD Serono, Inc. | $25 | Food and Beverage | In-kind items and services | Bavencio Drug, Oncology | 2020 | |
| 2020-01-22 | Astellas Pharma US Inc | $24 | Food and Beverage | In-kind items and services | XOSPATA Drug, ONCOLOGY | 2020 | |
| 2020-01-21 | Rigel Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | Tavalisse Drug, Hematology | 2020 | |
| 2020-01-16 | GENZYME CORPORATION | $19 | Food and Beverage | In-kind items and services | CABLIVI Biological, Hematology | 2020 | |
| 2020-01-14 | Celgene Corporation | $20 | Food and Beverage | Cash or cash equivalent | INREBIC Drug, Hematology | 2020 | |
| 2020-01-13 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2020 | |
| 2020-01-08 | Secura Bio, Inc. | $13 | Food and Beverage | Cash or cash equivalent | Farydak Drug, Oral Oncologic | 2020 | |
| 2020-01-08 | Secura Bio, Inc. | $0 | Food and Beverage | Cash or cash equivalent | Farydak Drug, Oral Oncologic | 2020 | |
| 2020-01-06 | Bayer Healthcare Pharmaceuticals Inc. | $18 | Food and Beverage | In-kind items and services | Stivarga Drug, Oncology | 2020 | |
| 2019-12-16 | Pharmacyclics LLC, an AbbVie Company | $19 | Food and Beverage | In-kind items and services | Imbruvica Drug, Oncology | 2019 | |
| 2019-12-13 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | TECENTRIQ Biological, BioOncology | 2019 | |
| 2019-12-11 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | PROMACTA Drug, ONCOLOGY | 2019 | |
| 2019-12-03 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | VOTRIENT Drug, ONCOLOGY | 2019 | |
| 2019-12-02 | GENZYME CORPORATION | $15 | Food and Beverage | In-kind items and services | CABLIVI Drug, RARE BLOOD DISORDERS | 2019 | |
| 2019-11-22 | Bayer Healthcare Pharmaceuticals Inc. | $15 | Food and Beverage | In-kind items and services | Nexavar Drug, Oncology | 2019 | |
| 2019-11-20 | Partner Therapeutics, Inc. | $14 | Food and Beverage | In-kind items and services | Leukine Drug, Hematology | 2019 | |
| 2019-11-19 | Celgene Corporation | $21 | Food and Beverage | In-kind items and services | Revlimid Drug, Hematology / Oncology | 2019 | |
| 2019-11-14 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2019 | |
| 2019-11-11 | EUSA Pharma (US) LLC | $16 | Food and Beverage | In-kind items and services | Sylvant Biological, Hematology Oncology | 2019 | |
| 2019-11-07 | Takeda Pharmaceuticals U.S.A., Inc. | $20 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-11-06 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | IMFINZI Drug, Oncology | 2019 | |
| 2019-11-05 | Janssen Biotech, Inc. | $20 | Food and Beverage | In-kind items and services | Balversa Drug, Oncology | 2019 | |
| 2019-11-04 | Takeda Pharmaceuticals U.S.A., Inc. | $23 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-06-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | GILOTRIF Drug, ONCOLOGY | 2019 | |
| 2019-06-19 | Merck Sharp & Dohme LLC | $18 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2022-02-10 | Novartis Pharmaceuticals Corporation | FLORIDA CANCER RESEARCH INSTITUTE LLC | $2,242 | MONALEESA 3 A RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED STUDY OF RIBOCICLIB IN COMBINATION WITH FULVESTRANT FOR THE TREA | 2022 |
| 2020-11-11 | Novartis Pharmaceuticals Corporation | FLORIDA CANCER RESEARCH INSTITUTE | $600 | TRINITI1 A PHASE I AND OR II SINGLE ARM OPEN LABEL STUDY OF RIBOCICLIB IN COMBINATION WITH EVEROLIMUS PLUS EXEMESTANE IN | 2020 |
| 2020-01-09 | Novartis Pharmaceuticals Corporation | FLORIDA CANCER RESEARCH INSTITUTE | $611 | AN OPEN LABEL MULTICENTER PHASE IIIB STUDY OF RIBOCICLIB LEE011 IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTM | 2020 |
| 2019-06-08 | PUMA BIOTECHNOLOGY, INC. | Florida Cancer Care And Florida Cancer Research Institute | $3,160 | A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib | 2019 |
| 2019-05-23 | Novartis Pharmaceuticals Corporation | FLORIDA CANCER RESEARCH INSTITUTE | $2,231 | AN OPEN LABEL MULTICENTER PHASE IIIB STUDY OF RIBOCICLIB LEE011 IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTM | 2019 |
| 2019-04-03 | Novartis Pharmaceuticals Corporation | FLORIDA CANCER RESEARCH INSTITUTE LLC | $838 | MONALEESA 3 A RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED STUDY OF RIBOCICLIB IN COMBINATION WITH FULVESTRANT FOR THE TREA | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Ruskin, FL, county Hillsborough County, FL, state Florida; placed by its city name.
| Measure | Place (city or town) Ruskin, FL | County Hillsborough County, FL | State Florida |
|---|---|---|---|
| Population B01003 | 29,834 | 1,522,748 | 22,416,077 |
| Population, 2020 census P1 | 28,620 | 1,459,762 | 21,538,187 |
| Median age B01002 | 35.0 | 37.9 | 42.6 |
| Under 18 B01001 | 27.5% | 21.6% | 19.5% |
| 65 and over B01001 | 11.1% | 15.0% | 21.3% |
| Households B11001 | 10,197 | 583,192 | 8,752,810 |
| Foreign born B05002 | 14.0% | 19.7% | 21.9% |
| Median household income B19013 | $79,235 | $79,540 | $74,568 |
| Median family income B19113 | $86,726 | $96,725 | $89,891 |
| Per capita income B19301 | $31,968 | $44,342 | $42,609 |
| Poverty rate B17001 | 10.8% | 12.7% | 12.6% |
| Unemployment rate B23025 | 4.5% | 4.5% | 4.8% |
| Civilian labor force B23025 | 14,790 | 802,809 | 11,016,578 |
| Mean commute (minutes) B08013 | 35.6 | 28.8 | 28.0 |
| Bachelor's degree or higher B15003 | 22.4% | 38.1% | 34.1% |
| Housing units B25001 | 11,516 | 630,692 | 10,256,470 |
| Owner-occupied B25003 | 75.4% | 61.5% | 67.6% |
| Renters B25003 | 24.6% | 38.5% | 32.4% |
| Median home value B25077 | $323,000 | $371,500 | $359,000 |
| Median gross rent B25064 | $1,419 | $1,667 | $1,669 |
| White, not Hispanic B03002 | 35.3% | 44.8% | 50.4% |
| Black B03002 | 24.2% | 15.3% | 14.6% |
| Hispanic or Latino B03002 | 33.6% | 30.4% | 27.4% |
| Asian B03002 | 1.7% | 4.5% | 2.9% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 4.4% in Sep 2026 (4.2% a year earlier); per capita personal income $78,345 in 2025, up 38% in five years (+11.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Ruskin, FL.
Comments